Solid Tumors

BeiGene is advancing a solid tumor pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. Among these are tislelizumab, a monoclonal antibody against PD-1 and ociperlimap, a monoclonal antibody against TIGIT.
All Types
All Types
Reading
4
Slide-Kit
6
Video
5
Latest
Latest
latest
Oldest
oldest
All Types
All Types
Reading
4
Slide-Kit
6
Video
5
Latest
Latest
latest
Oldest
oldest
Suggested:
CLL
EHA
ESMO
Hematologic Malignancies
Solid Tumors
WM

Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind and inhibit TIGIT. Watch the mode of action (MoA) video to learn more.

Video
29 May 2024

Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD‑1. Watch the mode of action (MoA) video to learn more.

Video
29 May 2024